Healthcare Afterhours Loser in Focus: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

The insider ownership percentage is the key indicator, can be used by investors, to measure the outlook of senior management has on their company. Insider ownership for the REGN is 20.20%. Institutional ownership refers to the ownership stake in a company that is held by large financial organizations, pension funds or endowments. The Institutional ownership for the REGN is 73.60%.

Insider trading is the buying or selling of any publicly traded company’s stock and this can be done by someone who has non-public, material information about that REGN. Insider trading can be illegal or legal depending on when the insider makes the trade. It is illegal when the material information is still non-public. The insider transactions of the company (6-month change in insider ownerships) for the Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is -0.06%.

Institutional transactions is the amount of a Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s available stock owned by mutual or pension funds, insurance companies, investment firms, private foundations, endowments or other large entities that actually manage the funds on the behalf of others, so its an interesting element for the traders to note it, and the Institutional ownership for the REGN is 1.55%.

A Healthcare sector firm, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stock slumped -2.12% on Wednesday and when day-trade ended the stock finally concluded at $301.43 and number of shares that changed hands during the day are 1.52 Million. The number of shares REGN stock currently held by all its shareholders are 106.93 and floated shares, the number of shares are available for trading in an open market on last trading day are 79.33. The average volume of shares for 3 months is 906.64 and REGN stock value has moved between $295.52 – 443.28 in last one year.
[finviz ticker=REGN]
The Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s latest earnings date is 8/6/2019. The Gross margin is the difference between the revenue and the cost of goods sold (COGS), divided by revenue. In other words, Gross Margin is a percentage value, while Gross Profit is a monetary value. The valuable gross margin for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is 93.40% and the profit margin is 35.10% and the stock has gained -19.30% in 2019 to date.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s monthly stock performance is -0.93%, the quarterly performance is -23.83%, the half year performance is calculated as -24.12%. The yearly performance of REGN is -18.82%.

The higher the volatility, the riskier the security. For example, when the stock market rises and falls more than one percent over a sustained period of time, it is called a “volatile” market, if the stock price stays relatively stable, the security has low volatility. The Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) weekly volatility is measured as 3.88% and monthly volatility measured as 3.05%.

Return on assets (ROA) is a main indicator of how profitable a company is relative to its total assets. REGN return on assets is 21.40%, the return on equity (ROE) of the Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is 29.20%, while the most important return on investment is calculates as a percentage and is typically used for personal financial decisions, and REGN return on investment is 24.90%.

The price to earnings ratio is 14.68, price to sales ratio is 4.66, and price to book ratio is 3.48, price to cash per share ration is 9.97, price to free cash flow is 15.38.

Analysts mean target price for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is $405.16 while analysts mean recommendation is 2.60. The current share price indicates that stock is -31.80% away from its one year high and is moving 2.09% ahead of its 52-week low. REGN’s distance from 20 day simple moving average is -3.04% and distance from 50-Day simple moving average is -3.89%.

See also  Laggard: Prevail Therapeutics Inc. (NASDAQ:PRVL)

Leave a Reply